129 related articles for article (PubMed ID: 38415537)
1. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract][Full Text] [Related]
2. CD44
Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
[TBL] [Abstract][Full Text] [Related]
3. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.
Meng E; Long B; Sullivan P; McClellan S; Finan MA; Reed E; Shevde L; Rocconi RP
Clin Exp Metastasis; 2012 Dec; 29(8):939-48. PubMed ID: 22610780
[TBL] [Abstract][Full Text] [Related]
4. Are CD44
Ryspayeva DE; Smolanka II; Dudnichenko АS; Lyashenko AA; Grinevich YA; Gurianov VG; Koshubarova MV; Seleznev AA
Exp Oncol; 2017 Sep; 39(3):224-228. PubMed ID: 28967636
[TBL] [Abstract][Full Text] [Related]
5. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.
Nagare RP; Sneha S; Sidhanth C; Roopa S; Murhekar K; Shirley S; Swaminathan R; Sridevi V; Ganesan TS
Cancer Biomark; 2020; 28(3):397-408. PubMed ID: 32224528
[TBL] [Abstract][Full Text] [Related]
6. ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24- phenotype.
Zhong Y; Shen S; Zhou Y; Mao F; Guan J; Lin Y; Xu Y; Sun Q
Med Oncol; 2014 Mar; 31(3):864. PubMed ID: 24519209
[TBL] [Abstract][Full Text] [Related]
7. Expression of CD44
Sihombing UHM; Andrijono ; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
Gynecol Oncol Rep; 2022 Aug; 42():101005. PubMed ID: 35707599
[TBL] [Abstract][Full Text] [Related]
8. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis.
Yong CS; Ou Yang CM; Chou YH; Liao CS; Lee CW; Lee CC
BMC Gastroenterol; 2012 Jul; 12():95. PubMed ID: 22839505
[TBL] [Abstract][Full Text] [Related]
9. Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer.
Seo AN; Lee HJ; Kim EJ; Jang MH; Kim YJ; Kim JH; Kim SW; Ryu HS; Park IA; Im SA; Gong G; Jung KH; Kim HJ; Park SY
Br J Cancer; 2016 May; 114(10):1109-16. PubMed ID: 27115469
[TBL] [Abstract][Full Text] [Related]
10. CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
Motohara T; Fujimoto K; Tayama S; Narantuya D; Sakaguchi I; Tashiro H; Katabuchi H
Obstet Gynecol; 2016 Jun; 127(6):1003-1011. PubMed ID: 27159753
[TBL] [Abstract][Full Text] [Related]
11. A CD44⁻/CD24⁺ phenotype is a poor prognostic marker in early invasive breast cancer.
Ahmed MA; Aleskandarany MA; Rakha EA; Moustafa RZ; Benhasouna A; Nolan C; Green AR; Ilyas M; Ellis IO
Breast Cancer Res Treat; 2012 Jun; 133(3):979-95. PubMed ID: 22119938
[TBL] [Abstract][Full Text] [Related]
12. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
Hurt EM; Kawasaki BT; Klarmann GJ; Thomas SB; Farrar WL
Br J Cancer; 2008 Feb; 98(4):756-65. PubMed ID: 18268494
[TBL] [Abstract][Full Text] [Related]
13. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44, CD24 and ESA in pancreatic adenocarcinoma cell lines varies with local microenvironment.
Wei HJ; Yin T; Zhu Z; Shi PF; Tian Y; Wang CY
Hepatobiliary Pancreat Dis Int; 2011 Aug; 10(4):428-34. PubMed ID: 21813394
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
[TBL] [Abstract][Full Text] [Related]
16. [Pilot study on the correlation between high incidence of CD44+/CD24 -/low/ABCG2- cells and poor prognosis in breast cancer].
Gong JF; Yuan YH; Song GH; Yu J; Han Y; Jia J; Ren J
Beijing Da Xue Xue Bao Yi Xue Ban; 2008 Oct; 40(5):465-70. PubMed ID: 18931706
[TBL] [Abstract][Full Text] [Related]
17. The role of ALDH1A1 in contributing to breast tumour aggressiveness: A study conducted in an African population.
Gyan E; Green A; Ahenkorah-Fondjo L; Jackson A; Toss MS; Akakpo PK; Derkyi-Kwarteng L; Rahman GA; Owiredu W
Ann Diagn Pathol; 2021 Apr; 51():151696. PubMed ID: 33460998
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of CD24 and CD44 in breast cancer: a meta-analysis.
Wang Z; Wang Q; Wang Q; Wang Y; Chen J
Int J Biol Markers; 2017 Mar; 32(1):e75-e82. PubMed ID: 27470135
[TBL] [Abstract][Full Text] [Related]
19. CD44 and CD24 coordinate the reprogramming of nasopharyngeal carcinoma cells towards a cancer stem cell phenotype through STAT3 activation.
Shen YA; Wang CY; Chuang HY; Hwang JJ; Chi WH; Shu CH; Ho CY; Li WY; Chen YJ
Oncotarget; 2016 Sep; 7(36):58351-58366. PubMed ID: 27521216
[TBL] [Abstract][Full Text] [Related]
20. Autophagy positively regulates the CD44(+) CD24(-/low) breast cancer stem-like phenotype.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Martin-Castillo B; Vellon L; Menendez JA
Cell Cycle; 2011 Nov; 10(22):3871-85. PubMed ID: 22127234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
